Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3421-3425

  Al Shagahin, Hani ^a   Alkotyfan, Khaled ^a   Müller, Hans Helge ^a   Sesterhenn, Andreas M ^a   Werner, Jochen A ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cut off level; Cyfra 21 1; Follow up; Hypopharyngeal squamous cell carcinoma; Laryngeal squamous cell carcinoma; Local recurrence; Tumor marker

Indexed keywords

CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPOPHARYNX CANCER; KRUSKAL WALLIS TEST; LARYNX CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOPHARYNGEAL NEOPLASMS; KERATIN-19; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 68549094337     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Jovanovic B and Vokes EE: competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res 10: 1956-1962, 2004.
2. Forastiere A, Koch W, Trotti A and Sidransky D: Medical progress - head and neck cancer. N Eng J Med 345: 1890-1900, 2001.
3. Hanna EYN, Papay FA, Gupta MK, Lavertu P and Tucker HM: Serum tumor markers of head and neck cancer. Head Neck 12: 50-59, 1990.
4. Moll R, Divo M and Langbein L: The human keratins: biology and pathology. Histochem Cell Biol 129: 705-733, 2008.
5. Bodenmuller H, Ofenloch-Hahnle B, Lane EB, Dessauer A, Bottgar V and Donie F: Lung cancer-associated keratin 19 fragments: development and biochemical charecterisation of the new serum assay Enzymun-Test Cyfra 21-1. Int J Biol Markers 9: 75-81, 1994. (Pubitemid 24225517)
6. Niemann AM, Paulsen JJ, Lippert BM, Henze E, Gorogh T and Gottschlich S: Cyfra21-1 in patients with head and neck cancer. In: Head and Neck Cancer: Advances in Basic Research. Werner JA, Lippert BM and Rudert HH (eds.). Amsterdam, Elsevier, pp. 529-537, 1996.
7. Niemann AM, Goeroegh T, Gottschlich S, Lippert BM and Werner JA: Cut-off value determination of Cyfra 21-1 for squamous cell carcinoma of the head and neck. Anticancer Res 17: 2859-2860, 1997. (Pubitemid 27434804)
8. Sobin LH and Wittekind CH: Head and Neck Tumours. In: TNM Classification of Malignant Tumours, 6th edition. Sobin LH and Wittekind CH (eds.). New Jersey, John Wiley & Sons, pp. 31-50, 2002.
9. Banal A, Hacene K, Berthelot-Ruff E, Mahe E, Fontana X and Pichon MF: Comparison of Cyfra 21-1 and SCC assays in head and neck tumors. Tumor Biol 22: 27-35, 2001. (Pubitemid 30816526)
10. Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M and Gruener N: Cyfra 21-1 A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 121: 177-181, 1995.
11. Barak V, Goike H, Panaretakis KW and Einarsson R: Clinical utility of cytokeratins as tumor markers. Clin Biochem 37: 529-540, 2004. (Pubitemid 38845016)
12. Doweck I, Barak M, Uri N and Greenberg E: The prognostic value of the tumor marker Cyfra 21 -1 in carcinoma of the head and neck and its role in early detection of recurrent disease. Br J Cancer 83: 1696-1701, 2000. (Pubitemid 32001716)
13. Deng YF, Chen P, Lin YZ, Le JZ, Wu XL, Yu MQ, Zhuang PY and Gao MH : Analytical and clinical evaluation of Cyfra 21-1 by electrochemiluminscent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol 117: 190-194, 2003. (Pubitemid 36286643)
14. Maass JD, Hoffmann-Fazel A, Goeroegh T, Hoffmann M, Meyer JE, Gottschlich S, Rudert H and Maune S: Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer. Anticancer Res 20: 2241-2243, 2000. (Pubitemid 30636216)
15. Hoffmann-Fazel A, Hoffmann M, Gottschlich S, Maass JD, Rudert H, Maune S: Cyfra 21-1 in diagnosis of distant metastases of head and neck carcinoma. Anticancer Res 23: 917-920, 2003. (Pubitemid 36750895)
16. Pradier O, Hille A, Schmiberger H and Hess CF: Monitoring of therapy in head and neck cancer patients during the radiotherapy by measurments of Cyfra 21-1. Cancer Radiother 6: 15-21, 2002. (Pubitemid 34169501)
17. Wollenberg B, Jan V, Schmit UM, Hofmann K, Stieber P and Fateh-Moghadam A: Cyfra 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell carcinoma. Anticancer Res 16: 3117-3124, 1996.
18. Lo WY, Tsai MH, Tsai Y, Hua CH, Tsai FJ and Huang SY: Identification of overexpressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin Chim Acta 376: 101-107, 2007. (Pubitemid 44880973)
19. Baker H, Patel V, Molinolo AA, Shillitoe EJ, Ensley JF and Yoo GH: Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture micro dissection and tandem mass spectrometry. Oral Oncol 41: 183-199, 2005. (Pubitemid 40202885)
20. Sawant SS, Zingde SM and Vaidya MM: Cytokeratin fragments in the serum: Their utility for the management of oral cancer. Oral Oncology 44: 722-732, 2008.
21. Céruse P, Rabilloud M, Charrié A, Dubreul C and Distant F: Study of Cyfra 21-1, a tumor marker, in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol 114: 768-776, 2005. (Pubitemid 41502379)